Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

This is written in the approval document.

Reimbursement

CDS

Citation

Vemurafenib Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6723/102_v6_Vemurafenib_Monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) BRAF p.V600E Melanoma Vemurafenib
HSE (1) BRAF p.V600K Melanoma Vemurafenib

Contributions

Date Contributor Description
2024-01-16 Van Allen lab Adding HSE approvals for reimbursement to database
2013-03-07 Health Service Executive Indication approved for reimbursement.